 BetterLife Pharma Inc CSE:BETR, OTCQB:BETRF has announced that an abstract from the preclinical data on anti-depressant activity of its lead compound 2-bromo-LSD BETR-001 has been accepted for presentation at the Canadian Association for Neuroscience CAN Conference from May 12-15, 2022 in Toronto, Canada. The Vancouver-based company said the study, led by Dr Vern Lewis, is part of its collaboration with the laboratory of Dr Argel Aguilar-Valles at Carleton Universitys Department of Neuroscience. 